The global human insulin market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of diabetes and obesity in developing countries, which are driving the demand for insulin products. Insulin analogs and biosimilars are expected to be the fastest-growing segment in this market during the forecast period.
Insulin analogs and biosimilars accounted for more than 50% share of total revenue generated by human insulin products in 2017, owing to their high efficacy and safety profile as compared with other types of human insulin products such as human insulin biologics or short-acting insulins. Insulin analogs have been used extensively since they were introduced in 1982 due to their ability to mimic natural physiological processes that control blood glucose levels. Biosimilars are also gaining traction due to their lower cost as compared with branded drugs, which has led them being prescribed more often by physicians across various regions such as North America, Europe, Asia Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA).
North America accounted for over 40% share of total revenue generated by human insulin products globally in 2017 owing mainly due its large population size and high prevalence rates for diabetes among adults aged 20 years or older. The region is also home to some major players such as Eli Lilly & Company Inc, Novo Nordisk A/S., Sanofi S.A., Pfizer Inc, Merck & Co., Inc, AstraZeneca plc among others who have a strong presence here owing primarily due its large population size and high prevalence rates for diabetes among adults aged 20 years or older.
- The global population is aging and the number of people with diabetes is increasing.
- The cost of insulin has increased, which has led to a decrease in the use of insulin by patients who are uninsured or underinsured.
- Insulin prices have increased due to patent expiration, which has led to an increase in competition among manufacturers and a decrease in prices for consumers.
- There are new technologies that allow for more accurate dosing and delivery methods that may lead to better patient outcomes and lower costs for patients with diabetes who require insulin therapy.
- There is an increase in the number of people diagnosed with type 2 diabetes, which will lead to an increase in demand for insulin.
Industry Growth Insights published a new data on “Human Insulin Market”. The research report is titled “Human Insulin Market research by Types (Insulin Analogs and Biosimilars, Human Insulin Biologics), By Applications (Short acting, Intermediate acting, Long acting, Pre-mix Insulin), By Players/Companies B. Braun, Becton, Dickinson, Biocon, Biodel, ELI Lilly, Julphar, NOVO Nordisk, Sanofi, Wockhardt, Ypsomed”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Human Insulin Market Research Report
By Type
Insulin Analogs and Biosimilars, Human Insulin Biologics
By Application
Short acting, Intermediate acting, Long acting, Pre-mix Insulin
By Companies
B. Braun, Becton, Dickinson, Biocon, Biodel, ELI Lilly, Julphar, NOVO Nordisk, Sanofi, Wockhardt, Ypsomed
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Human Insulin Market Report Segments:
The global Human Insulin market is segmented on the basis of:
Types
Insulin Analogs and Biosimilars, Human Insulin Biologics
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Short acting, Intermediate acting, Long acting, Pre-mix Insulin
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- B. Braun
- Becton, Dickinson
- Biocon
- Biodel
- ELI Lilly
- Julphar
- NOVO Nordisk
- Sanofi
- Wockhardt
- Ypsomed
Highlights of The Human Insulin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Insulin Analogs and Biosimilars
- Human Insulin Biologics
- By Application:
- Short acting
- Intermediate acting
- Long acting
- Pre-mix Insulin
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Human Insulin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Human insulin is a hormone that helps the body use glucose for energy. It is produced by the pancreas and released into the bloodstream when food is eaten. Insulin helps to transport glucose from the blood to cells, where it can be used for energy.
Some of the major companies in the human insulin market are B. Braun, Becton, Dickinson, Biocon, Biodel, ELI Lilly, Julphar, NOVO Nordisk, Sanofi, Wockhardt, Ypsomed.
The human insulin market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Human Insulin Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Human Insulin Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Human Insulin Market - Supply Chain
4.5. Global Human Insulin Market Forecast
4.5.1. Human Insulin Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Human Insulin Market Size (000 Units) and Y-o-Y Growth
4.5.3. Human Insulin Market Absolute $ Opportunity
5. Global Human Insulin Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Human Insulin Market Size and Volume Forecast by Type
5.3.1. Insulin Analogs and Biosimilars
5.3.2. Human Insulin Biologics
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Human Insulin Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Human Insulin Market Size and Volume Forecast by Application
6.3.1. Short acting
6.3.2. Intermediate acting
6.3.3. Long acting
6.3.4. Pre-mix Insulin
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Human Insulin Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Human Insulin Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Human Insulin Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Human Insulin Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Human Insulin Demand Share Forecast, 2019-2026
9. North America Human Insulin Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Human Insulin Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Human Insulin Market Size and Volume Forecast by Application
9.4.1. Short acting
9.4.2. Intermediate acting
9.4.3. Long acting
9.4.4. Pre-mix Insulin
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Human Insulin Market Size and Volume Forecast by Type
9.7.1. Insulin Analogs and Biosimilars
9.7.2. Human Insulin Biologics
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Human Insulin Demand Share Forecast, 2019-2026
10. Latin America Human Insulin Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Human Insulin Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Human Insulin Market Size and Volume Forecast by Application
10.4.1. Short acting
10.4.2. Intermediate acting
10.4.3. Long acting
10.4.4. Pre-mix Insulin
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Human Insulin Market Size and Volume Forecast by Type
10.7.1. Insulin Analogs and Biosimilars
10.7.2. Human Insulin Biologics
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Human Insulin Demand Share Forecast, 2019-2026
11. Europe Human Insulin Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Human Insulin Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Human Insulin Market Size and Volume Forecast by Application
11.4.1. Short acting
11.4.2. Intermediate acting
11.4.3. Long acting
11.4.4. Pre-mix Insulin
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Human Insulin Market Size and Volume Forecast by Type
11.7.1. Insulin Analogs and Biosimilars
11.7.2. Human Insulin Biologics
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projectins by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Human Insulin Demand Share, 2019-2026
12. Asia Pacific Human Insulin Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Human Insulin Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Human Insulin Market Size and Volume Forecast by Application
12.4.1. Short acting
12.4.2. Intermediate acting
12.4.3. Long acting
12.4.4. Pre-mix Insulin
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Human Insulin Market Size and Volume Forecast by Type
12.7.1. Insulin Analogs and Biosimilars
12.7.2. Human Insulin Biologics
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Human Insulin Demand Share, 2019-2026
13. Middle East & Africa Human Insulin Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Human Insulin Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Human Insulin Market Size and Volume Forecast by Application
13.4.1. Short acting
13.4.2. Intermediate acting
13.4.3. Long acting
13.4.4. Pre-mix Insulin
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Human Insulin Market Size and Volume Forecast by Type
13.7.1. Insulin Analogs and Biosimilars
13.7.2. Human Insulin Biologics
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Human Insulin Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Human Insulin Market: Market Share Analysis
14.2. Human Insulin Distributors and Customers
14.3. Human Insulin Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. B. Braun
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Becton, Dickinson
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Biocon
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Biodel
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. ELI Lilly
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Julphar
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. NOVO Nordisk
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Sanofi
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Wockhardt
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Ypsomed
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
